ADC Therapeutics Stock Falls as Safety Worries Overshadow Strong ZYNLONTA Trial Results
ADC Therapeutics fell by nearly half after ZYNLONTA showed better cancer control but higher rates of serious side effects and deaths.
NOTRELOAD AI
CrowdStrike Q1 2027 Earnings: Beats Expectations, Raises Guidance Despite Higher AI Spending
Despite beating Q1 estimates and raising full-year guidance, CrowdStrike shares plunged after hours as operating expenses surged 15% on heavy AI investments.
Broadcom’s Q3 Outlook Lets Down Investors Expecting a Blowout
Broadcom reported $22.2B revenue and 143% AI growth in Q2 2026, but shares dropped after Q3 guidance fell short of Wall Street’s blowout expectations.
Navitas Stock Surges as Nvidia MGX AI Deal Goes Live at COMPUTEX
Navitas Semiconductor surged following a release detailing its collaboration with NVIDIA on data center racks, but analysts remain skeptical.
FDA Fast-Tracks Verastem’s Breakthrough Oral Drug for KRAS G12D Lung Cancer
Verastem’s VS-7375 pill targets KRAS G12D lung cancer, a rare, hard-to-treat mutation with no approved drugs yet.
Mineralys Therapeutics Raises $650M+ in Capital Blitz to Clear Path for Lorundrostat Launch
Mineralys raised cash via $150M stock sale, $500M loan, and $200M royalty buyout to fund drug ahead of FDA decision; stock fell.